Contineum Therapeutics/$CTNM

1D1W1MYTD1Y5YMAX

About Contineum Therapeutics

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Ticker
$CTNM
Sector
Health
Primary listing
NASDAQ
Employees
51
Headquarters
San Diego, United States
Website
www.contineum-tx.com

CTNM Metrics

BasicAdvanced
$494M
-
-$1.72
0.74
-

What the Analysts think about CTNM

Analyst ratings (Buy, Hold, Sell) for Contineum Therapeutics stock.
Analyst projections of the future price of Contineum Therapeutics stock.

Bulls say / Bears say

PIPE-791 has advanced into a global Phase 2 trial for idiopathic pulmonary fibrosis, with more than 55 sites active across eight countries. Its roughly 324-patient study gives Contineum a substantial near-term test of its lead drug in a serious disease. (AP News)
Early results suggest PIPE-791 may have potential beyond lung disease: in a small Phase 1b chronic-pain study, patients generally showed greater numerical improvement than placebo across exploratory pain measures. The drug was also well tolerated, although the efficacy findings still need confirmation. (Business Wire)
Contineum reported $236.6 million in cash, cash equivalents and marketable securities at the end of June, and expects this to fund operations through mid-2029. That provides a substantial cushion to run its current clinical programme without an immediate need to raise capital. (AP News)
PIPE-307 failed to meet the main efficacy goal in a Phase 2 depression trial, weakening the value of Contineum’s partnered programme. Johnson & Johnson is still reviewing exploratory results, but its next steps remain uncertain. (Reuters)
The Phase 2 IPF study is not expected to finish until around mid-2028, and it has yet to show that PIPE-791 improves lung function. With PIPE-307’s depression setback, Contineum’s prospects are increasingly concentrated in an unproven lead programme. (AP News, Reuters)
Contineum continues to record losses and expects research and development spending to rise as it advances its trials. Its cash runway is finite, so delays, higher costs or disappointing results could eventually require new financing or cuts to development plans. (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2026.

CTNM Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

CTNM Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

CTNM News

AllArticlesVideos

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

Business Wire3 weeks ago

Funds containing CTNM

AllUSDGBPEUR
Funds
Fund name
Fund size
$CTNM weighting
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.03%
iShares Nasdaq US Biotechnology£BTEK
£865M0.03%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.01%
SPDR Russell 2000 US Small Cap£R2SC
£4.1B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.